Skip to Content

Gazyva Approval History

Gazyva (obinutuzumab) is a CD20-directed cytolytic antibody indicated for the combination treatment of patients with chronic lymphocytic leukemia and follicular lymphoma.

Development History and FDA Approval Process for Gazyva

Nov 16, 2017Approval FDA Approves Genentech’s Gazyva for Previously Untreated Advanced Follicular Lymphoma
Feb 26, 2016Approval FDA Approves Genentech’s Gazyva (obinutuzumab) for Certain People with Previously Treated Follicular Lymphoma
Nov  1, 2013Approval FDA Approves Gazyva for Chronic Lymphocytic Leukemia

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.